For instance, the activating mutations of the epidermal growth factor receptor (EGFR) gene (EGFR-mut) have been observed in 15% (Europe) to 62% (Asia) of lung adenocarcinoma cases [2,7]. This evidence concerns the gene EGFR and lung adenocarcinoma.